What is the target price for Radius Health stock?
On average, they expect Radius Health's stock price to reach $25.60 in the next twelve months. This suggests a possible upside of 90.3% from the stock's current price. View analysts' price targets for Radius Health or view top-rated stocks among Wall Street analysts. Who are Radius Health's key executives?
Is fast radius (fast) stock a buy or sell?
Fast Radius has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings. According to analysts' consensus price target of $4.00, Fast Radius has a forecasted upside of 200.8% from its current price of $1.33.
Is Radi stock a buy at $19?
Among the bulls is Credit Suisse analyst Sami Badri, who rates RADI an Outperform (i.e. Buy) along with a $19 price target. This figure indicates a 46% upside for the coming year. (To watch Badri’s track record, click here)Backing his bullish stance, Badri writes: “We forecast RADI to grow revenues at ~21% CAGR through 2023E on a normalized basis…
Should I buy or sell Radius Health stock right now?
5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last twelve months. There are curre...
What is Radius Health's stock price forecast for 2022?
5 brokerages have issued 12-month price targets for Radius Health's shares. Their RDUS stock forecasts range from $7.00 to $10.00. On average, they...
How has Radius Health's stock price performed in 2022?
Radius Health's stock was trading at $6.92 at the start of the year. Since then, RDUS shares have increased by 2.2% and is now trading at $7.07. V...
When is Radius Health's next earnings date?
Radius Health is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Radius...
How were Radius Health's earnings last quarter?
Radius Health, Inc. (NASDAQ:RDUS) announced its earnings results on Thursday, May, 5th. The biopharmaceutical company reported ($0.39) earnings per...
Who are Radius Health's key executives?
Radius Health's management team includes the following people: Mr. G. Kelly Martin , CEO, Pres & Director (Age 63, Pay $612.37k) Mr. Salvador Gr...
Who are some of Radius Health's key competitors?
Some companies that are related to Radius Health include Sierra Oncology (SRRA) , Ligand Pharmaceuticals (LGND) , BELLUS Health (BLUSF) , Madri...
What other stocks do shareholders of Radius Health own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include NVIDIA (NVDA) , Gilea...
What is Radius Health's stock symbol?
Radius Health trades on the NASDAQ under the ticker symbol "RDUS."
When will Radius release its results?
(NASDAQ: RADI) (the "Company"), one of the largest global aggregators of real property interests underlying wireless communications cell sites and other communications infrastructure, today announced that it will release its first quarter financial results on Wednesday, May 12, 2021.
When will Radius release its third quarter results?
(NASDAQ: RADI) (the "Company") today announced that it will release its third quarter financial results prior to the market open on Thursday, November 11, 2021. Management will host a webcast and conference call at 8:30 A.M. Eastern Time to review financial results, discuss recent events and conduct a question-and-answer session. A copy of the earnings release and presentation slides will be posted to the "Quarterly Results" section
When will Radius warrants be redeemed?
As a result, each unexercised warrant will be redeemed by the Company for $0.01 per warrant after December 17, 2021. The Redemption Event has been tr
Who is the senior vice president of Radius?
(NASDAQ: RADI) ("Radius" or the "Company"), today announced the appointment of Jason Harbes as Senior Vice President of Investor Relations , effective immediately. In this role, Harbes will lead the development and execution of Radius’s global investor relations strategy and serve as the Company’s primary liaison with shareholders and the investment community.
Is Radius Global Infrastructure a Russell 3000 company?
Radius Global Infrastructure, Inc. (NASDAQ: RADI) ("Radius" or the "Company") today announced that it has been included on the preliminary list of additions to the Russell 3000® Index, which will become effective after the U.S. market closes on June 25.
What is Radius Health?
Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company's lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis; and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA.
What is the P/E ratio of Radius Health?
The P/E ratio of Radius Health is -10.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
What is the RDUS symbol?
Radius Health trades on the NASDAQ under the ticker symbol "RDUS."
Does Radius Health pay dividends?
Radius Health does not currently pay a dividend.
What is Radius Health?
Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine and other therapeutics. The company’s commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis.
Is Radius Health on RDUS?
Radius Health, Inc. is listed on NASDAQ under RDUS. You can buy Radius Health, Inc. stock through any online brokerage account such as E*TRADE, Charles Schwab, or Merrill Edge. Premium subscribers can easily link their Seeking Alpha portfolios to their brokerage account. (Your credentials will never be made accessible to Seeking Alpha.)
Is RDUS a neutral rating?
7 analysts have issued ratings. Wall Street analysts rate RDUS as Neutral on average, for a Wall Street consensus of hold. View RDUS’s ratings here.
When is the RDUS earnings call 2021?
RDUS earnings call for the period ending March 31, 2021.
When do shares push hire?
Shares push hire after the company reports earnings. Here's what investors need to know.